Clinical trials: Disease Progression
- Condition Disease Progression
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Myopia, Myopia Progression
Comparing Myopia Control Spectacle Lenses and Standard Single Vision Spectacle Lenses in Children With Myopia
The purpose of this clinical trial is to compare a new myopia control spectacle lens with a standard single vision spectacle lens in slowing the progression of myopia (nearsightedness) in healthy children aged 6 to under 11…
- Trial name
- PEARL (NCT07839091)
- Testing
- Investigational Myopia Control Spectacle Lens, Single Vision Spectacle Lens
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- Essilor International
Healthy Volunteer, Muscular Atrophy, Spinal
Ability of Muscle Imaging and Motor Function Measure (MFM) to Detect Changes in Disease Progression in Ambulant Spinal Muscular Atrophy Patients Compared to Healthy Volunteers.
This non-drug, single center, 24-week, longitudinal study in ambulant spinal muscular atrophy (SMA) patients and in age- and gender-matched healthy volunteers will assess the detection of disease progression by magnetic resonance…
- Trial name
- NCT02044029
- Where
- Switzerland
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Myopia, Myopia Progression
Myopia Control Spectacle Lens Cessation Study
To quantify myopic progression (cycloplegic spherical equivalent refraction - cSER) following the cessation of use of specific spectacle lenses.
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Trial name
- BIRCH (NCT05893979)
- Testing
- Spectacle Lenses
- Where
- 8 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Myopia
A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
A randomized, double-blind, placebo-controlled, multicenter, phase III clinical study of the efficacy and safety of two low-concentration atropine sulfate eye drops in slowing the progression of myopia in children
- Trial name
- China-CHAMP (NCT06209320)
- Testing
- Lower dose atropine sulfate eye drops, Low dose atropine sulfate eye drops
- Where
- China
- Volunteers
- 777 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Myopia, Child Myopia Progression
Effect of MiYOSMART iQ Spectacle Lenses on Myopia Progression in Children
This prospective, single-center study aims to evaluate the efficacy and safety of MiYOSMART iQ spectacle lenses with DIMS (Defocus Incorporated Multiple Segments) and Triple Enhanced Design (TED) technology in slowing myopia…
- Trial name
- NCT07387159
- Testing
- MiYOSMART iQ spectacle lenses
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- Hoya Lens Rus LLC
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Generalized Arterial Calcification of Infancy
Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 Deficiency
The purpose of this prospective study is to characterize the natural history of ENPP1 Deficiency and the early-onset form of ABCC6 Deficiency longitudinally.
- Conditions
- Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Generalized Arterial Calcification of Infancy, Autosomal Recessive Hypophosphatemic Rickets, Adenosine Triphosphate Binding Cassette Transporter Protein Subfamily C Member 6
- Trial name
- NCT05050669
- Testing
- No Intervention for this observational study
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 12 people
- Sponsor
- Inozyme Pharma
Choroideremia
Natural Disease Progression in Participants With Choroideremia
The primary objective of this study is to quantify disease progression measured by best corrected visual acuity (BCVA) in the real-world setting among Choroideremia (CHM) participants.
- Trial name
- NCT04795206
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 1,178 people
- Sponsor
- Biogen
Myopia, Myopia Progression
Spectacle Lens Visual Acuity Assessments Study
This is a two-arm parallel group, non-dispensing study. Participants will be existing active CYPRESS Extension (CPRO-1802-002) subjects. Subjects will undergo additional visual performance assessments.
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Trial name
- CEDAR (NCT05650190)
- Testing
- Novel spectacle lens design, Spectacle lenses
- Where
- 6 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Cystic Fibrosis, Pseudomonas Aeruginosa
Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
This program is to provide expanded access to aztreonam lysine for inhalation (AZLI) prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P.
- Trial name
- EAP (NCT00989807)
- Testing
- Aztreonam lysine
- Where
- 4 sites in Canada
- Sponsor
- Gilead Sciences
Myopia
Myoslow Lens Study to Control Myopia in Children
A Prospective, randomized, controlled double masked trial to assess the performance of Myoslow lens in slowing myopia progression in children.
- Trial name
- NCT06553404
- Testing
- Myoslow, Single Vision
- Where
- Israel
- Volunteers
- 125 people
- Sponsor
- Crystal Optic
Prostatic Neoplasms
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
The aim of this study was to evaluate the efficacy of two different doses of BIBF 1120 (250 mg twice daily versus 150 mg twice daily) in an exploratory manner.
- Trial name
- NCT02182063
- Testing
- BIBF 1120 low dose, BIBF 1120 high dose
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Retinal Dystrophies, Color Vision Defects
Natural History Study of Inherited Retinal Diseases
This prospective, observational investigation seeks to delineate the interplay between chromatic vision deficits and both functional visual outcomes and anatomical retinal biomarkers in individuals affected by Inherited Retinal…
- Conditions
- Retinal Dystrophies, Color Vision Defects, Vision Disorders, Macular Degeneration
- Trial name
- MojiLVCDT (NCT07085533)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Augelux Therapeutics
Myopia
Clinical Investigation of a Novel Spectacle Lens on Slowing Down Juvenile Myopia Progression
The goal of this exploratory clinical trial is to evaluate the efficacy and safety of a test spectacle lens (standard single vision lens (SVL) during first year, and standard myopia control lens (MCL) in second year), designed…
- Trial name
- NCT06850168
- Testing
- SVL, SVL with passive red-light emission, MCL
- Where
- Singapore
- Volunteers
- 35 people
- Sponsor
- Essilor International
Secondary Progressive Multiple Sclerosis (SPMS)
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients
This study is a single cohort, central registration system, all-case, open-label, multicenter observational study in patients using Mayzent for the indication of secondary progressive multiple sclerosis.
- Trial name
- NCT04593927
- Testing
- Mayzent
- Where
- 174 sites in Japan
- Volunteers
- 451 people
- Sponsor
- Novartis Pharmaceuticals
Atypical Hemolytic Uremic Syndrome
Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
This was a prospective, open-label study with no participant randomization. Treatment for aHUS was observational and at the discretion of the treating physician.
- Trial name
- EVIDENCE (NCT02614898)
- Testing
- Eculizumab
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 67 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Alport Syndrome Patients With eGFR Between 45-90 ml/Min/1.73 m2
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
There is limited published clinical data about the natural history of renal disease in Alport syndrome. The RG012-01 study will collect data to characterize the progression of renal dysfunction in Alport syndrome patients.
- Trial name
- RG012-01 (NCT02136862)
- Where
- 15 sites in United States, Australia and 4 more
- Volunteers
- 165 people
- Sponsor
- Genzyme, a Sanofi Company
Type 1 Diabetes Mellitus
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT
The intended purpose of this study was to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.
- Trial name
- NCT00751842
- Testing
- rhGAD65
- Where
- 43 sites in United States
- Volunteers
- 331 people
- Sponsor
- Diamyd Therapeutics AB
Myopia
Electronic Spectacles Versus Low Dose Atropine in Young Myopes
This is a bilateral, dispensing, masked, randomized clinical trial. Myopic children will be randomly assigned to one of the following: (1) Investigational clinical prototype (CP1) device without atropine, (2) Investigational CP1…
- Trial name
- NCT06034379
- Testing
- eSpectacle Clinical prototype (CP1) device, 0.01% atropine
- Where
- Taiwan
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Kubota Vision Inc.
Myopia, Myopia Progression, Lag of Accommodation, Hyperopic Retinal Blur, Reduction in Contrast
Lag of Accommodation With DOT Spectacle Lenses
The objective of the study is to measure the difference in the lag of accommodation between DOT spectacle lenses and control spectacles.
- Trial name
- ASH (NCT04700111)
- Testing
- DOT Pattern, Control Spectacles
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Rheumatoid Arthritis
Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents
This study was conducted to examine the safety profile and the effectiveness in daily clinical practice of adalimumab in rheumatoid arthritis participants showing rapid progression of structural damage of the joints, who had no…
- Trial name
- NCT01783730
- Volunteers
- 163 people
- Sponsor
- AbbVie